Form 4: BioMarin Director Slamon Exercises Stock Options and Disposes of Shares
SEC Form 4 Filing
Director Dennis Slamon exercised stock options and disposed of shares of BioMarin Pharmaceutical Inc. on March 18, 2024.
Summary
- On March 18, 2024, Dennis Slamon, a director of BioMarin Pharmaceutical Inc., exercised stock options to acquire 10,000 shares of common stock at a price of $79.70 per share.
- Following the exercise of the options, Slamon disposed of 9,510 shares of common stock at a price of $83.81 per share to cover tax obligations.
- After these transactions, Slamon directly owns 31,299 shares of BioMarin common stock.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing insider transactions, which is neutral in sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company insiders.
Comparison to Industry Standards
- Insider trading activity is a common occurrence in publicly traded companies, and the reporting requirements are standardized by the SEC.
- The Form 4 filing is a standard document used to report changes in beneficial ownership.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership.
Key Dates
| Date | Description |
|---|---|
| 2023-12-06 | Date of Power of Attorney execution. |
| 2024-03-18 | Date of stock option exercise and share disposal. |
| 2024-03-20 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.